Close Menu

miRNA

The company's lab is cleared in 48 states. The firm also said that it could earn $17 million through a license with Prometheus Laboratories.

The firm launched three microRNA-based tests during the fourth quarter, and posted a profit due to a capital gain on the sale of Auction Rate Securities to Credit Suisse. However, Rosetta only has enough cash to fund operations through mid-2010 and said that it may seek to raise additional funds.

An Affy spokesperson said the firm's interest in the market is an extension of its gene-expression profiling play, and said several "key advantages" over rival tools could enable it to profit in the market, which is poised to grow 25 percent through 2015.

An Italian research team demonstrated that miR-9 is up-regulated in two types of human immune cells during the pro-inflammatory process and may regulate a NF-kappa-B subunit.

Strands: Mar 12, 2009

Premium

Rosetta Genomics, Alnylam Pharmaceuticals, Massachusetts Institute of Technology

The company is looking to differentiate itself from other players in the miRNA array market — such as Agilent Technologies, Life Technologies, Exiqon, and Febit — by stressing the "quality, performance, and affordability" of its OneArray platform.

The firm published data from a study showing that the same biomarker used in its miRNA-based test for squamous lung cancer provided 96 percent sensitivity.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.